John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol […]
Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which
Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and
Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, Isofol Mob: +46 70
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)
